The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.The agent (Tecentriq Hybreza, Genentech) is the first subcutaneous anti-PD-L1 cancer immunotherapy approved in the ...

The 10-minute subcutaneous injection of ocrelizumab is administered by a healthcare provider and designed to be delivered without the need for IV infrastructure, Newsome pointed out.

Subcutaneous amivantamab-lazertinib demonstrated a safety profile consistent with historical intravenous data, with a 5-fold reduced rate and lower severity of IRRs and a reduced administration time ...

Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, discussed the continued use of subcutaneous daratumumab following initial ...

Subcutaneous administration of vedolizumab is now approved for maintenance therapy in adults with moderate to severe active Crohn's disease after induction therapy with intravenous vedolizumab.